AbbVie (ABBV)
(Delayed Data from NYSE)
$195.18 USD
-0.22 (-0.11%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $195.24 +0.06 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
AbbVie (ABBV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$195.59 | $218.00 | $138.00 | 0.10% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for AbbVie comes to $195.59. The forecasts range from a low of $138.00 to a high of $218.00. The average price target represents an increase of 0.1% from the last closing price of $195.40.
Analyst Price Targets (22)
Broker Rating
AbbVie currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 23 brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on 23 recommendations.
Of the 23 recommendations deriving the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 60.87% and 8.7% of all recommendations. A month ago, Strong Buy made up 60.87%, while Buy represented 8.7%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 14 | 14 | 13 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 7 | 7 | 7 | 7 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.81 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/30/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
7/26/2024 | UBS | Trung Huynh | Hold | Hold |
7/26/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
7/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/25/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
7/25/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
7/10/2024 | Atlantic Equities | Steven K Chesney | Strong Buy | Strong Buy |
6/5/2024 | Not Identified | Not Identified | Hold | Strong Buy |
5/17/2024 | Cantor Fitzgerald & Co | Louise Chen | Not Available | Strong Buy |
4/29/2024 | SVB Securities | David Risinger | Hold | Hold |
4/29/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
4/29/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
4/28/2024 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
3/22/2024 | Guggenheim Securities | Vamil Divan | Strong Buy | Strong Buy |
2/23/2024 | Berenberg Bank | Luisa Hector | Not Available | Hold |
12/11/2023 | Goldman Sachs | Chris Shibutani | Hold | Strong Buy |
10/9/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 23 |
Average Target Price | $196.05 |
LT Growth Rate | 6.70% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 95 of 253 |
Current Quarter EPS Est: | 2.95 |